Sublingual delivery of insulin:: Effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity

被引:24
作者
Cui, CY
Lu, WL [1 ]
Xiao, L
Zhang, SQ
Huang, YB
Li, SL
Zhang, RJ
Wang, GL
Zhang, X
Zhang, Q
机构
[1] Peking Univ, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
[2] Peking Univ, Sch Basic Med Sci, Beijing 100083, Peoples R China
[3] Peking Univ, Sch Stomatol, Beijing 100083, Peoples R China
[4] Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China
关键词
insulin; enhancing mechanism; transport; hypoglycemic activity; sublingual delivery;
D O I
10.1248/bpb.28.2279
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purposes of this study were to evaluate effects of enhancers for sublingual delivering insulin on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity in normal rats. The effects on sublingual mucosa, and aggregation states of insulin were estimated using fluorescence polarization, and circular dichroism method, respectively. The human immortalized oral epithelial cell monolayer was used for evaluating transport of insulin. Hydroxylpropyl-beta-cyclodextrin (HP-P-CD), chitosan, polyethylene-polyp ropylene glycol, polyoxyethylene lauryl ether, polysorbate 80, egg lecithin, or oleic acid, was used as a penetration enhancer, respectively. The fluidity of sublingual mucosal lipid was markedly reduced by these enhancers excluding polysorbate 80, and the secondary structure of the mucosal proteins was also influenced by these enhancers. The hexamers of insulin were dissociated to monomers only by chitosan, polyoxyethylene lauryl ether, and egg lecithin. Nonetheless, plasma glucose levels in normal rats were significantly lowered after sublingual administration of insulin with an enhancer compared with those without an enhancer at the same time-point. The enhancing effects may be due to one or multiple factors: increasing the mucosal lipid fluidity, directly loosing the tight junction of epithelia, and dissociating the hexamers of insulin to monomers. Among these, the opened tight junction may correlate most with the enhancing effect in the mucosal permeability. Because the aggregates of insulin exist, the dissociation of the aggregates by an enhancer would benefit the permeability.
引用
收藏
页码:2279 / 2288
页数:10
相关论文
共 47 条
[1]   In vitro polarized transport of L-phenylalanine in human nasal epithelium and partial characterization of the amino acid transporters involved [J].
Agu, R ;
Dang, HV ;
Jorissen, M ;
Willems, T ;
Vandoninck, S ;
Van Lint, J ;
Vandenheede, JV ;
Kinget, R ;
Verbeke, N .
PHARMACEUTICAL RESEARCH, 2003, 20 (08) :1125-1132
[2]   ADIP, a novel afadin- and α-actinin-binding protein localized at cell-cell adherens junctions [J].
Asada, M ;
Irie, K ;
Morimoto, K ;
Yamada, A ;
Ikeda, W ;
Takeuchi, M ;
Takai, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (06) :4103-4111
[3]   Buccal permeation of buspirone: Mechanistic studies on transport pathways [J].
Birudaraj, R ;
Berner, B ;
Shen, S ;
Li, XL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (01) :70-78
[4]   CINGULIN, A NEW PERIPHERAL COMPONENT OF TIGHT JUNCTIONS [J].
CITI, S ;
SABANAY, H ;
JAKES, R ;
GEIGER, B ;
KENDRICKJONES, J .
NATURE, 1988, 333 (6170) :272-276
[5]  
Da Violante G, 2004, BIOL PHARM BULL, V27, P1986
[6]   ENDOTHELIAL CELL-TO-CELL JUNCTIONS [J].
DEJANA, E ;
CORADA, M ;
LAMPUGNANI, MG .
FASEB JOURNAL, 1995, 9 (10) :910-918
[7]   OCCLUDIN - A NOVEL INTEGRAL MEMBRANE-PROTEIN LOCALIZING AT TIGHT JUNCTIONS [J].
FURUSE, M ;
HIRASE, T ;
ITOH, M ;
NAGAFUCHI, A ;
YONEMURA, S ;
TSUKITA, S ;
TSUKITA, S .
JOURNAL OF CELL BIOLOGY, 1993, 123 (06) :1777-1788
[8]   IDENTIFICATION OF A 160-KDA POLYPEPTIDE THAT BINDS TO THE TIGHT JUNCTION PROTEIN-ZO-1 [J].
GUMBINER, B ;
LOWENKOPF, T ;
APATIRA, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (08) :3460-3464
[9]   DRUG DELIVERY VIA THE MUCOUS-MEMBRANES OF THE ORAL CAVITY [J].
HARRIS, D ;
ROBINSON, JR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (01) :1-10
[10]  
ISHIDA M, 1981, CHEM PHARM BULL, V29, P810